Investig Clin Urol.  2019 Mar;60(2):114-119. 10.4111/icu.2019.60.2.114.

Patient utilization survey of mirabegron prescribed for overactive bladder

• Rahkola-Soisalo P
• Balcerzak
• Ruotsalainen J
• Mikkola TS

• KMID: 2438822
• DOI: http://doi.org/10.4111/icu.2019.60.2.114

Abstract

PURPOSE
Mirabegron, a β3-adrenoreceptor agonist, is used to treat overactive bladder. The factors affecting persistence of mirabegron use or symptom improvement are not thoroughly known, but could be related to patient characteristics. Therefore, we evaluated persistence of medication use, symptom improvement, and quality of life among Finnish mirabegron users. In addition, we assessed possible predictors of change in these variables.
MATERIALS AND METHODS
Participants (52 men, 118 women) with an initial mirabegron prescription were recruited nationwide from 79 pharmacies. Volunteers were interviewed at baseline and after 6 months. Subject and clinical characteristics, symptom severity, and quality of life (EQ-5D-5L) were assessed using a visual analogue scale.
RESULTS
Of 170 participants, 144 (84.7%) were reached after 6 months. The rate of persistent mirabegron use was 50.7%. Experiencing adverse effects (29.6%) was the most common reason for discontinuation of medication. A primary health care unit as a prescription site (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.03-4.9) was associated with increased risk for discontinuation. Mirabegron relieved symptoms in 45.2% and enhanced quality of life in 41.7% of the participants. Age < 64 years was associated with better probability of symptom improvement (OR, 2.7; 95% CI, 1.1-6.8), whereas none of the other parameters assessed predicted change in quality of life.
CONCLUSIONS
In this Finnish population, 50.7% of the participants continued using mirabegron after 6 months. The prescription site seemed to be important for persistent use, which may be related to patient counseling. Younger patients were more likely to benefit from treatment with mirabegron.

Keyword

Medication adherence; Quality of life; Urinary bladder; Urinary incontinence, urge

MeSH Terms

Counseling
Humans
Male
Medication Adherence
Pharmacies
Prescriptions
Primary Health Care
Quality of Life
Urinary Bladder
Urinary Bladder, Overactive*
Urinary Incontinence, Urge
Volunteers

Reference

1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. International Continence Society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009; 28:287. PMID: 19350662.

2. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014; 65:79–95. PMID: 24007713.

3. Vaughan CP, Johnson TM 2nd, Ala-Lipasti MA, Cartwright R, Tammela TL, Taari K, et al. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur Urol. 2011; 59:629–636. PMID: 21306820.

4. Pöyhönen A, Häkkinen JT, Koskimäki J, Hakama M, Tammela TL, Auvinen A. Empirical evaluation of grouping of lower urinary tract symptoms: principal component analysis of Tampere Ageing Male Urological Study data. BJU Int. 2013; 111:467–473. PMID: 23106935.

5. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013; 67:1015–1033. PMID: 24073974.

6. Altman D, Iliadou AN, Lundholm C, Milsom I, Pedersen NL. Somatic comorbidity in women with overactive bladder syndrome. J Urol. 2016; 196:473–477. PMID: 26907510.

7. Blasco P, Valdivia MI, Oña MR, Roset M, Mora AM, Hernández M. Clinical characteristics, beliefs, and coping strategies among older patients with overactive bladder. Neurourol Urodyn. 2017; 36:774–779. PMID: 27120009.

8. Chapple CR, Kaplan SA, Mitcheson D, Blauwet MB, Huang M, Siddiqui E, et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014; 21:960–967. PMID: 25092441.

9. Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, Ficarra V. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). BJU Int. 2015; 115:32–40. PMID: 24602031.

10. Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015; 9:343–350. PMID: 26644809.

11. Kim TH, Lee KS. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016; 57:84–93.

12. Duckett J, Balachandran A. Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. Int Urogynecol J. 2016; 27:1163–1167. PMID: 26803838.

13. National Advisory Board on Research Ethics in Finland. Ethical principles of research in the humanities and social and behavioural sciences and proposals for ethical review [Internet]. Helsinki: National Advisory Board on Research Ethics in Finland;2009. Available from: http://www.tenk.fi/sites/tenk.fi/files/ethicalprinciples.pdf.

14. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16:199–208. PMID: 10109801.

15. Pindoria N, Malde S, Nowers J, Taylor C, Kelleher C, Sahai A. Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn. 2017; 36:404–408. PMID: 26669282.

16. Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017; 72:389–399. PMID: 28196724.

17. Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K. Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial. Low Urin Tract Symptoms. 2018; 10:148–152. PMID: 27911988.

18. Bunn F, Kirby M, Pinkney E, Cardozo L, Chapple C, Chester K, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015; 69:199–217. PMID: 25495905.

19. de Ridder D, Roumeguère T, Kaufman L. Overactive bladder symptoms, stress urinary incontinence and associated bother in women aged 40 and above; a Belgian epidemiological survey. Int J Clin Pract. 2013; 67:198–204. PMID: 23409688.

20. Pavesi M, Devlin N, Hakimi Z, Nazir J, Herdman M, Hoyle C, et al. Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron. J Med Econ. 2013; 16:866–876. PMID: 23647446.